Trial Profile
An open-label study of the efficacy and safety of oral CEP-701 [lestaurtinib] for the treatment of patients with advanced multiple myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Sep 2006
Price :
$35
*
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Sep 2006 Status change
- 24 Jul 2006 New trial record.